Where Will AbbVie Be in 5 Years?
A lot has changed for (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity in the U.S. in 2023. Despite that setback, AbbVie has produced solid returns over the last half a decade.
But can the drugmaker maintain that momentum through 2031? Let's find out how things might unfold for AbbVie over the next five years.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
177,75 €
0,20 %
Mit 32 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ist AbbVie Inc. einer der Lieblinge unserere Community.
Das von der Community festgelegte Kursziel von 209 € für AbbVie Inc. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 177.75 € hin.
